Multi-Disciplinary Expert Perspective on the Management of Type 2 Inflammation-Driven Severe CRSwNP: A Brief Overview of Pathophysiology and Recent Clinical Insights
DOI: https://doi.org/10.2147/jaa.s447093
2024-05-09
Journal of Asthma and Allergy
Abstract:Sanna Toppila-Salmi, 1, 2 Leif Bjermer, 3 Lars-Olaf Cardell, 4, 5 Anders Cervin, 6, 7 Tuuli Heinikari, 2 Lauri Lehtimäki, 8, 9 Marie Lundberg, 10 Jens C Richter, 11 Saara Sillanpää 9, 12 1 Department of Otorhinolaryngology, Kuopio University Hospital and School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 2 Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 3 Department of Clinical Sciences, Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 4 Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; 5 Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden; 6 Centre for Clinical Research, University of Queensland, Brisbane, Australia; 7 Faculty of Medicine, Lund University, Lund, Sweden; 8 Allergy Centre, Tampere University Hospital, Tampere, Finland; 9 Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; 10 Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 11 Department of Asthma and Allergology, Clinic of Lung Medicine, Skåne University Hospital and Lund University, Lund, Sweden; 12 Department of Otorhinolaryngology and Head and Neck Surgery, Tampere University Hospital, Tampere, Finland Correspondence: Sanna Toppila-Salmi, Haartmaninkatu 3, Haartman Institute, University of Helsinki, Helsinki, 00014, Finland, Email Severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a disabling airway disease that significantly impacts patients' lives through the severity of symptoms, the need for long-term medical treatment and the high risk of recurrence post-surgery. Biological agents targeting type 2 immune responses underlying the pathogenesis of CRSwNP have shown effectiveness in reducing polyp size and eosinophilic infiltrate, and in decreasing the need for additional sinus surgeries. However, despite recent progress in understanding and treating the disease, type 2 inflammation-driven severe CRSwNP continues to pose challenges to clinical management due to several factors such as persistent inflammation, polyp recurrence, heterogeneity of disease, and comorbidities. This article presents the findings of a scientific discussion involving a panel of ear, nose and throat (ENT) specialists and pulmonologists across Sweden and Finland. The discussion aimed to explore current management practices for type 2 inflammation-driven severe CRSwNP in the Nordic region. The main topics examined encompassed screening and referral, measurements of disease control, treatment goals, and future perspectives. The experts emphasized the importance of a collaborative approach in the management of this challenging patient population. The discussion also revealed a need to broaden treatment options for patients with type 2 inflammation-driven CRSwNP and comorbid conditions with shared type 2 pathophysiology. In light of the supporting evidence, a shift in the disease model from the presence of polyps to that of type 2 inflammation may be warranted. Overall, this discussion provides valuable insights for the scientific community and can potentially guide the future management of CRSwNP. Keywords: chronic rhinosinusitis, type 2 immunity, surgery, biological therapy, Nordic countries, collaboration Chronic rhinosinusitis (CRS) is defined by the presence of sinonasal symptoms such as nasal blockage/obstruction/congestion or nasal discharge, persisting for 12 weeks or more. 1 CRS is a clinical syndrome comprising a group of disorders with different phenotypes and degrees of severity. 2 Phenotypically, it is divided into CRS with nasal polyps (CRSwNP) and without (CRSsNP). 1 CRS has a multi-factorial etiology comprising alterations in mucociliary clearance, epithelial cell barrier abnormalities, and tissue remodeling. 3 The main pathomechanisms in CRS appear to involve dysfunctional interactions between the host and environmental stressors at the sinonasal mucosa, arising from an interplay between genetic/epigenetic factors and exposure to infectious agents or airborne irritants. 4 Around one in ten people are thought to suffer from CRS in Europe, 5 although estimates vary across geographical regions. 6 CRSwNP accounts for up to 20% of all CRS cases and is more debilitating than the phenotype without nasal polyposis. 7 Epidemiological studies such as the large, m -Abstract Truncated-
immunology,allergy,respiratory system